ING2 Antibody(Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9H160 |
---|---|
Clone Names | 100623195 |
Gene ID | 3622 |
---|---|
Other Names | Inhibitor of growth protein 2, Inhibitor of growth 1-like protein, ING1Lp, p32, p33ING2, ING2, ING1L |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ING2 |
---|---|
Synonyms | ING1L |
Function | Seems to be involved in p53/TP53 activation and p53/TP53- dependent apoptotic pathways, probably by enhancing acetylation of p53/TP53. Component of a mSin3A-like corepressor complex, which is probably involved in deacetylation of nucleosomal histones. ING2 activity seems to be modulated by binding to phosphoinositides (PtdInsPs). |
Cellular Location | Nucleus. Note=Predominantly nuclear. Localized to chromatin and nuclear matrix Upon reduced PtdIns(5)P levels seems to be released from chromatin and, at least partially, translocated to the cytoplasm |
Tissue Location | Widely expressed. Higher expressed in colon-cancer tumor than in normal colon tissues. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene is a member of the inhibitor of growth (ING)family. Members of the ING family associate with and modulate theactivity of histone acetyltransferase (HAT) and histone deacetylase(HDAC) complexes and function in DNA repair and apoptosis.
References
Ythier, D., et al. Oncogene 29(44):5946-5956(2010)Larrieu, D., et al. EMBO Rep. 10(10):1168-1174(2009)Kumamoto, K., et al. Int. J. Cancer 125(6):1306-1315(2009)Borkosky, S.S., et al. J. Cancer Res. Clin. Oncol. 135(5):703-713(2009)Unoki, M., et al. FEBS Lett. 582(28):3868-3874(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.